Inhibrx Biosciences, Inc. (INBX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
Inhibrx Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 22 | $443.08 | $2,005.52 | $1,562.44 | 352.63% |
 Joseph Castro Nuveen LLC | 17,177 | $244,938.26 | $1.58M | $1.34M | 546.44% |
 Li Peng China Universal Asset Management Co. Ltd. | 2,581 | $50,680.14 | $237,090.66 | $186,410.52 | 367.82% |
 Michael Byun SageView Advisory Group LLC | 28 | $2,212 | $2,476.32 | $264.32 | 11.95% |
| DWC David W. Chenet Presidio Capital Management LLC | 3,394 | $268,126 | $300,776.28 | $32,650.28 | 12.18% |
Inhibrx Biosciences, Inc. (INBX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inhibrx Biosciences, Inc. ever had a stock split?
Inhibrx Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark Lappe CEO | NASDAQ (NGS) Exchange | 45720N103 CUSIP |
| US Country | 109 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Inhibrx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutic candidates. Since its inception in 2009, the company has been committed to addressing unmet medical needs across various diseases, primarily in oncology and genetic disorders. Leveraging advanced technology and scientific research, Inhibrx, Inc. aims to bring forth novel treatments that can significantly improve patient outcomes. Headquartered in La Jolla, California, the company is at the forefront of biotechnology research, holding promising potential in its developmental pipeline. Its strategic partnerships with industry leaders like 2seventy bio, Inc. and Bristol-Myers Squibb Company further underscore its commitment to advancing healthcare solutions.
Products and Services
INBRX-109
INBRX-109 is a tetravalent therapeutic candidate that targets death receptor 5 (DR5). This innovative approach is aimed at treating various types of cancers, including chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma. Currently, INBRX-109 is undergoing Phase 2 clinical trials, highlighting its potential in oncology.
INBRX-101
Another notable candidate in Inhibrx's pipeline is INBRX-101. This product is designed as an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic, targeting patients suffering from AAT deficiency. By addressing this genetic disorder at its source, INBRX-101 aims to offer a new treatment paradigm for those affected. The candidate is in Phase 1 clinical trials, reflecting its early-stage development.
INBRX-106
INBRX-106 stands out as a hexavalent agonist of OX40, geared towards treating a broad range of oncology indications. Through its innovative mechanism of action, INBRX-106 is designed to stimulate the immune system in a manner that specifically targets and attacks cancer cells. The development of INBRX-106 underlines Inhibrx’s commitment to expanding its oncology portfolio with cutting-edge therapeutic solutions.
